PRINCETON, N.J., June 02, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health
specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products
announced today that Al Altomari, President and Chief Executive Officer will present at the Jefferies 2016 Healthcare
Conference on June 10, 2016 at 10:30 AM Eastern Time.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile
Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60
days following the event.
About Agile
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and
commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with
contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate Twirla®
(ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive
patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology called
Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch
adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
